- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT00401505
Rubella Susceptibility in Multiparous Women
February 20, 2019 updated by: Unity Health Toronto
The purpose of this study is to determine the reasons why multiparous women (women who are pregnant and have been pregnant before) might still be susceptible to rubella.
Study Overview
Detailed Description
This study is designed to investigate why multiparous women might still be susceptible to rubella.
All pregnant women are checked for rubella immunity, and if they are non-immune, there are standard orders in our hospital to administer the rubella vaccine on the post-partum floor prior to discharge home from the hospital.
Despite this, some multiparous women are found to be susceptible (non-immune), and this study will explore the reasons for this.
Study Type
Observational
Enrollment (Actual)
310
Contacts and Locations
This section provides the contact details for those conducting the study, and information on where this study is being conducted.
Study Locations
-
-
Ontario
-
Toronto, Ontario, Canada, M5B 1W8
- St. Michael's Hospital
-
-
Participation Criteria
Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.
Eligibility Criteria
Ages Eligible for Study
- Child
- Adult
- Older Adult
Accepts Healthy Volunteers
No
Genders Eligible for Study
Female
Sampling Method
Probability Sample
Study Population
All rubella susceptible women who delivered during the study period.
Description
Inclusion Criteria:
- All rubella susceptible women who delivered during the study period.
Study Plan
This section provides details of the study plan, including how the study is designed and what the study is measuring.
How is the study designed?
Design Details
- Observational Models: Cohort
- Time Perspectives: Retrospective
Collaborators and Investigators
This is where you will find people and organizations involved with this study.
Sponsor
Investigators
- Principal Investigator: Mark H Yudin, MD, MSc, Unity Health Toronto
Study record dates
These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.
Study Major Dates
Study Start
September 1, 2006
Primary Completion (Actual)
September 1, 2012
Study Completion (Actual)
September 1, 2012
Study Registration Dates
First Submitted
November 17, 2006
First Submitted That Met QC Criteria
November 17, 2006
First Posted (Estimate)
November 20, 2006
Study Record Updates
Last Update Posted (Actual)
February 22, 2019
Last Update Submitted That Met QC Criteria
February 20, 2019
Last Verified
February 1, 2019
More Information
Terms related to this study
Keywords
Additional Relevant MeSH Terms
Other Study ID Numbers
- 06-186
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Rubella
-
PT Bio FarmaCompletedMeasles | Congenital Rubella InfectionIndonesia
-
GlaxoSmithKlineCompletedMeasles; Mumps; Rubella | Measles-Mumps-Rubella VaccineUnited States, Finland, Taiwan, Estonia, Puerto Rico
-
Centers for Disease Control and PreventionInternational Centre for Diarrhoeal Disease Research, Bangladesh; Ministry...CompletedMeasles | Rubella | Rubella Syndrome, CongenitalBangladesh
-
PATHCompletedMeasles Antibody Seroconversion | Rubella Antibody Seroconversion | Rotavirus Geometric Mean Titer (GMT) | Rotavirus Immunoglobulin A (IgA) SeropositivityBangladesh
-
GlaxoSmithKlineCompletedMeasles | Rubella | Mumps | Measles-Mumps-Rubella VaccineUnited States, Puerto Rico
-
GlaxoSmithKlineCompletedMeasles | Rubella | Mumps | Measles-Mumps-Rubella VaccineFinland, Thailand, United States, Spain, Czechia, Puerto Rico, Malaysia
-
GlaxoSmithKlineCompletedMeasles-Mumps-RubellaTaiwan, United States, Korea, Republic of